{
    "organizations": [],
    "uuid": "23fb07410edf91871a6a9134828e1213a15e87fa",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-bergenbio-promising-data-highlight/brief-bergenbio-promising-data-highlighting-selective-axl-inhibitor-idUSFWN1RV01S",
    "ord_in_thread": 0,
    "title": "BRIEF-BerGenBio: Promising Data Highlighting Selective AXL Inhibitor",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 18 (Reuters) - BERGENBIO ASA:\n* BERGENBIO: PROMISING DATA HIGHLIGHTING SELECTIVE AXL INHIBITOR\n* DATA HIGHLIGHT BEMCENTINIBâ€™S POTENTIAL TO REVERSE TUMOUR IMMUNE SUPPRESSION AND ENHANCE IMMUNE CHECKPOINT INHIBITOR EFFICACY Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-18T14:10:00.000+03:00",
    "crawled": "2018-04-19T15:21:39.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "bergenbio",
        "asa",
        "bergenbio",
        "promising",
        "data",
        "highlighting",
        "selective",
        "axl",
        "inhibitor",
        "data",
        "highlight",
        "bemcentinib",
        "potential",
        "reverse",
        "tumour",
        "immune",
        "suppression",
        "enhance",
        "immune",
        "checkpoint",
        "inhibitor",
        "efficacy",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}